CD19 expression was also assessed in tumor biopsies from a subset of patients with R/R DLBCL before and after tafasitamab treatment in the L-MIND study.37 Of 8 lymph node biopsies taken after tafasitamab treatment, 3 were taken within 85 days (or 5 tafasitamab half-lives) of last treatment with tafasitamab, and 5 were taken at >85 days. Here, CD19 is linked to neoplasm.